This webinar will review case studies of three disease states that have trended against the payor goal of increasingly affordable treatment over time. Once genericized, treatment for osteoporosis, atopic dermatitis, and now nasal polyposis, face increasing pharmacy budget costs from emergent medications and indications. Following a brief overview of each category a guest panelist and veteran in managed care pharmacy management will discuss potential payor strategies to address this increasing challenge.
- John Messina, PharmD
Sr. VP, Clinical Development & Medical Affairs, Optinose
- James Kenney, MBA, RPh
Founder & President, JTKENNEY, LLC
Managed Care Pharmacy Consulting